Logo

Signal Genetics to Collaborate with Array BioPharma

Sep 23, 2010

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Signal Genetics today said that it will use its MyPRS genomic testing platform in a multiple myeloma research program being conducted by Array BioPharma.

According to the New York-based firm, it will provide Array BioPharma with genetic information from patient samples in two upcoming clinical studies on an Array drug candidate. It said that the collaboration may lead to the development of "superior and personalized treatment options for myeloma patients."

Signal Genetics runs a CLIA lab in Little Rock, Ark., and aims to help guide treatment regimens through analysis of patients' specific genetic expression profile.

Filed under

Microarrays & Multiplexing
Gene Expression Research
Diagnostics
Cancer
Research Funding
research alliance
multiple myeloma
gene expression
microarrays
personalized medicine
Signal Genetics
Breaking News
The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.